Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Upcoming Events

Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes

While attending DDW 2025, join us to discover the impact of IBS-C on patients’ QoL and find out how to apply advances in its treatment & management. 

Live Broadcast
1.00 available credits
Information
May 4, 2025
09:30 PM - 10:30 PM ET
Virtual
ReachMD Healthcare Image

This broadcast will start in exactly:

  • 0

    Day(s)

  • 0

    Hour(s)

  • 0

    Minute(s)

  • 0

    Second(s)

ENROLL
Details
Presenters

  • Overview

    Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. IBS-C has a multifactorial pathophysiology that includes altered gastrointestinal motility, visceral hypersensitivity, dysregulated brain-gut interactions, and microbiome-immune imbalances. This complexity requires a comprehensive understanding of IBS-C to effectively manage the care of patients. Traditional treatments often fall short of addressing the full scope of these interconnected mechanisms, leaving many patients with suboptimal symptom control and a diminished quality of life. Our symposium will provide practical and engaging discussions to help you better understand the impact of IBS-C on your patients’ quality of life, the pathophysiology behind the disease, and the clinical data supporting the use of new treatment options. 

    This program is not affiliated with Digestive Disease Week®

  • Program Schedule*

    6:30pm – 6:35pm: Welcome and Introductions
    6:35pm – 6:50pm: Understanding the Full Impact of IBS-C: Patient Quality of Life and the Limitations of Current IBS-C Management Strategies
    6:50pm – 7:05pm: The Science Behind IBS-C: Linking Pathophysiology to Treatment
    7:05pm – 7:20pm: New Horizons in IBS-C Treatment: Assessing FDA-Approved Medications
    7:20pm – 7:30pm: Conclusion and Audience Q&A Session
    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:
    Darren M. Brenner, MD, AGAF, FACG, RFF
    Professor of Medicine  
    Northwestern University
    Chicago, IL

    Dr. Brenner has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, Anji, Ardelyx, Bayer, Blueprint Meds, CinPhloro, Dr. Reddy, Gemelli, Ironwood, Laborie, Mahana, Salix, Vibrant
    Ownership Interest: Owlstone Pharma

    Faculty:
    William D. Chey, MD, AGAF, FACG, FACP, RFF
    H. Marvin Pollard Professor of Gastroenterology
    Professor of Nutrition Sciences
    Chief, Division of Gastroenterology
    Michigan Medicine
    Ann Arbor, MI

    Dr. Chey has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, ACG, Ardelyx, Biomerica, Gemelli, GI Health Foundation, IFFGD, Ironwood, Nestle, QOL Medical, Phathom, RedHill, Rome, Salix/Valeant, Takeda, Vibrant
    Research: Commonwealth Diagnostics International, FDA, NIH, Salix/Valeant
    Ownership Interest: Coprata, Dieta, Evinature, FoodMarble, Kiwi Bioscience, ModifyHealth
    Patent Holder: My Nutrition Health, Digital Manometry, Rectal Expulsion Device

    Kimberly D. Orleck, PA-C
    Director of Advanced Practice Providers
    Atlanta Gastroenterology Associates
    Atlanta, GA

    Ms. Orleck has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, Ardelyx, Janssen, Lilly, Pfizer, Salix, Takeda

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
    • Rosanne Strauss, PharmD, has no relevant relationships to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess the comprehensive and significant impact of irritable bowel syndrome with constipation (IBS-C) on patients' overall quality of life 
    • Understand the multifactorial pathophysiology of IBS-C and its effects on treatment outcomes
    • Evaluate the efficacy and safety of the new FDA-approved medications for IBS-C 

  • Target Audience

    This activity has been designed to meet the educational needs of gastroenterologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with irritable bowel syndrome with constipation (IBS-C).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is UAN JA0006235-0000-25-017-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).


    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Ardelyx, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Recommended

  • Overview

    Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. IBS-C has a multifactorial pathophysiology that includes altered gastrointestinal motility, visceral hypersensitivity, dysregulated brain-gut interactions, and microbiome-immune imbalances. This complexity requires a comprehensive understanding of IBS-C to effectively manage the care of patients. Traditional treatments often fall short of addressing the full scope of these interconnected mechanisms, leaving many patients with suboptimal symptom control and a diminished quality of life. Our symposium will provide practical and engaging discussions to help you better understand the impact of IBS-C on your patients’ quality of life, the pathophysiology behind the disease, and the clinical data supporting the use of new treatment options. 

    This program is not affiliated with Digestive Disease Week®

  • Program Schedule*

    6:30pm – 6:35pm: Welcome and Introductions
    6:35pm – 6:50pm: Understanding the Full Impact of IBS-C: Patient Quality of Life and the Limitations of Current IBS-C Management Strategies
    6:50pm – 7:05pm: The Science Behind IBS-C: Linking Pathophysiology to Treatment
    7:05pm – 7:20pm: New Horizons in IBS-C Treatment: Assessing FDA-Approved Medications
    7:20pm – 7:30pm: Conclusion and Audience Q&A Session
    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:
    Darren M. Brenner, MD, AGAF, FACG, RFF
    Professor of Medicine  
    Northwestern University
    Chicago, IL

    Dr. Brenner has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, Anji, Ardelyx, Bayer, Blueprint Meds, CinPhloro, Dr. Reddy, Gemelli, Ironwood, Laborie, Mahana, Salix, Vibrant
    Ownership Interest: Owlstone Pharma

    Faculty:
    William D. Chey, MD, AGAF, FACG, FACP, RFF
    H. Marvin Pollard Professor of Gastroenterology
    Professor of Nutrition Sciences
    Chief, Division of Gastroenterology
    Michigan Medicine
    Ann Arbor, MI

    Dr. Chey has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, ACG, Ardelyx, Biomerica, Gemelli, GI Health Foundation, IFFGD, Ironwood, Nestle, QOL Medical, Phathom, RedHill, Rome, Salix/Valeant, Takeda, Vibrant
    Research: Commonwealth Diagnostics International, FDA, NIH, Salix/Valeant
    Ownership Interest: Coprata, Dieta, Evinature, FoodMarble, Kiwi Bioscience, ModifyHealth
    Patent Holder: My Nutrition Health, Digital Manometry, Rectal Expulsion Device

    Kimberly D. Orleck, PA-C
    Director of Advanced Practice Providers
    Atlanta Gastroenterology Associates
    Atlanta, GA

    Ms. Orleck has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, Ardelyx, Janssen, Lilly, Pfizer, Salix, Takeda

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
    • Rosanne Strauss, PharmD, has no relevant relationships to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess the comprehensive and significant impact of irritable bowel syndrome with constipation (IBS-C) on patients' overall quality of life 
    • Understand the multifactorial pathophysiology of IBS-C and its effects on treatment outcomes
    • Evaluate the efficacy and safety of the new FDA-approved medications for IBS-C 

  • Target Audience

    This activity has been designed to meet the educational needs of gastroenterologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with irritable bowel syndrome with constipation (IBS-C).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is UAN JA0006235-0000-25-017-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).


    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Ardelyx, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Recommended

Schedule15 Feb 2025
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended